MedPath

To compare the effect of Phalatrikadi Kwath and Vrinda Triphaladi Kwath in obesity

Phase 4
Recruiting
Conditions
Obesity, unspecified, (2) ICD-10 Condition: E669||Obesity, unspecified, Patients of either sex between 21 to 51 yr with BMI ranging from 25.0 to 35 Kg/m2,
Registration Number
CTRI/2018/07/015075
Lead Sponsor
Chaudhary Brahm Prakash Ayurved Charak Sansthan
Brief Summary

According to the inclusion and exclusion criteria patients will be randomly selected from OPD and IPD of Chaudhary Brahm Prakash Ayurved Charak Sansthan

Khera Dabar Najafgarh New Delhi

Informed written consent will be taken from all the subjects included in the study

Patients will be randomly divided into 2 groups of 20 patients each

In group A 20 patients will be given *Phalatrikadi kwatha* in dose of   40 ml after mixing 12 gm of *haridra kalka* and 12 ml of honey in it twice in a day empty stomach

in morning and four hour after lunch for 21 days

20 patients will be given *Vrinda-Triphaladi kwatha* in dose of 40 ml after mixing 12 gm of *haridra kalka* and 12 ml of honey in it twice in a day empty stomach in

morning and four hour after lunch for 21 days

A proforma will be prepared for diagnosis of disease and assessment of subjects

BMI Weight Waist circumference Hip Circumference Waist hip Ratio Subjective symptoms and Objective symptoms will be assessed before and after treatment and

during follow up

Lipid profile will be done before and after treatment

Assessment of abdominal discomfort and abdominal pain and will also be done 0 day 7th day 14th day and 21st day

All the patients will be advised to follow the guidelines regarding *pathya-apathya* as described in Classical *Ayurvedic* texts during the trial period

Data will be statistically analyzed at the end of the study period

All the ethical issues will be maintained during the clinical trial

Detailed Description

Not available

Recruitment & Eligibility

Status
Open to Recruitment
Sex
All
Target Recruitment
40
Inclusion Criteria

BMI ranging from 25.0 to 35 Kg/m2 Patients willing to participate and provide signed informed consent.

Exclusion Criteria

Patients with Hypothyroidism Patients suffering from drug induced Obesity Patients with Diabetes Patients with severe Hypertension Patients with Renal Hepatic and Cardiac involvement Pregnant and Lactating women Patients having Gastro intestinal discomfort Patients who are not willing to participate with the study 9.Any other condition which may jeopardize the study.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Reduction in WeightWeight | BMI | Waist circumference | Hip circumference | Waist – Hip Ratio | subjective criteria of Sthaulya | on 0 day 21st day and 35th day | Serum VLDL | Serum LDL | Serum Triglycerides | Serum Total Cholesterol | Serum HDL | on 0 day and 21st day
Reduction in BMIWeight | BMI | Waist circumference | Hip circumference | Waist – Hip Ratio | subjective criteria of Sthaulya | on 0 day 21st day and 35th day | Serum VLDL | Serum LDL | Serum Triglycerides | Serum Total Cholesterol | Serum HDL | on 0 day and 21st day
Reduction in Waist circumferenceWeight | BMI | Waist circumference | Hip circumference | Waist – Hip Ratio | subjective criteria of Sthaulya | on 0 day 21st day and 35th day | Serum VLDL | Serum LDL | Serum Triglycerides | Serum Total Cholesterol | Serum HDL | on 0 day and 21st day
Reduction in Hip circumferenceWeight | BMI | Waist circumference | Hip circumference | Waist – Hip Ratio | subjective criteria of Sthaulya | on 0 day 21st day and 35th day | Serum VLDL | Serum LDL | Serum Triglycerides | Serum Total Cholesterol | Serum HDL | on 0 day and 21st day
Reduction in Waist – Hip RatioWeight | BMI | Waist circumference | Hip circumference | Waist – Hip Ratio | subjective criteria of Sthaulya | on 0 day 21st day and 35th day | Serum VLDL | Serum LDL | Serum Triglycerides | Serum Total Cholesterol | Serum HDL | on 0 day and 21st day
Reduction in Serum VLDLWeight | BMI | Waist circumference | Hip circumference | Waist – Hip Ratio | subjective criteria of Sthaulya | on 0 day 21st day and 35th day | Serum VLDL | Serum LDL | Serum Triglycerides | Serum Total Cholesterol | Serum HDL | on 0 day and 21st day
Reduction in Serum LDLWeight | BMI | Waist circumference | Hip circumference | Waist – Hip Ratio | subjective criteria of Sthaulya | on 0 day 21st day and 35th day | Serum VLDL | Serum LDL | Serum Triglycerides | Serum Total Cholesterol | Serum HDL | on 0 day and 21st day
Reduction in Serum TriglyceridesWeight | BMI | Waist circumference | Hip circumference | Waist – Hip Ratio | subjective criteria of Sthaulya | on 0 day 21st day and 35th day | Serum VLDL | Serum LDL | Serum Triglycerides | Serum Total Cholesterol | Serum HDL | on 0 day and 21st day
Reduction in Serum Total Cholesterol and an increase in Serum HDLWeight | BMI | Waist circumference | Hip circumference | Waist – Hip Ratio | subjective criteria of Sthaulya | on 0 day 21st day and 35th day | Serum VLDL | Serum LDL | Serum Triglycerides | Serum Total Cholesterol | Serum HDL | on 0 day and 21st day
Reduction in percentage relief in subjective criteria of SthaulyaWeight | BMI | Waist circumference | Hip circumference | Waist – Hip Ratio | subjective criteria of Sthaulya | on 0 day 21st day and 35th day | Serum VLDL | Serum LDL | Serum Triglycerides | Serum Total Cholesterol | Serum HDL | on 0 day and 21st day
Secondary Outcome Measures
NameTimeMethod
Assessment of reduction in the level of abdominal discomfort pain and Frequency of defecation during use of trial medicineslevel of abdominal discomfort pain and Frequency of defecation

Trial Locations

Locations (1)

Chaudhary Brahm Prakash Ayurved Charak Sansthan Khera Dabar New Delhi

🇮🇳

Delhi, DELHI, India

Chaudhary Brahm Prakash Ayurved Charak Sansthan Khera Dabar New Delhi
🇮🇳Delhi, DELHI, India
Prof Dr N R Singh
Principal investigator
9560659728
naimishraj@yahoo.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.